1 |
Wauthier L, Plebani M, Favresse J. Interferences in immunoassays: review and practical algorithm. Clin Chem Lab Med 2022. [PMID: 35304841 DOI: 10.1515/cclm-2021-1288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
2 |
Ghazal K, Brabant S, Prie D, Piketty ML. Hormone Immunoassay Interference: A 2021 Update. Ann Lab Med 2022;42:3-23. [PMID: 34374345 DOI: 10.3343/alm.2022.42.1.3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
3 |
Ishikawa T, Sakai H, Itaya T, Hirotsugu S, Shikuma J, Miwa T, Suzuki R, Odawara M. Falsely diagnosed thyrotoxicosis caused by anti-streptavidin antibodies and pre-wash procedures. Thyroid Res 2021;14:17. [PMID: 34246285 DOI: 10.1186/s13044-021-00108-y] [Reference Citation Analysis]
|
4 |
Wouters Y, Oosterbos J, Reynaert N, Penders J. Alarmed by misleading interference in free T3 and free T4 assays: a new case of anti-streptavidin antibodies. Clin Chem Lab Med 2020;58:e69-71. [PMID: 31605576 DOI: 10.1515/cclm-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Ruth I, Mathieu E, Burniat A, Fage D, Cotton F, Wolff F. Interferences in free thyroxine concentration using the Roche analytical platform: improvement of the third generation? Clin Chem Lab Med 2020;58:e36-9. [PMID: 31377735 DOI: 10.1515/cclm-2019-0525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
6 |
Ricci V, Esteban MP, Sand G, Menises MM. Interference of anti-streptavidin antibodies: More common than we thought? In relation to six confirmed cases. Clin Biochem 2021;90:62-5. [PMID: 33545112 DOI: 10.1016/j.clinbiochem.2021.01.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
7 |
Dahll LK, Haave EM, Dahl SR, Aas FE, Thorsby PM. Endogenous anti-streptavidin antibodies causing erroneous laboratory results more common than anticipated. Scandinavian Journal of Clinical and Laboratory Investigation 2021;81:92-103. [DOI: 10.1080/00365513.2020.1858493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
8 |
Favresse J, Stoefs A, Bayart JL, Burlacu MC, Maisin D, Maiter D, Gruson D. A Challenging Case of Falsely Elevated Free Thyroid Hormones. J Appl Lab Med 2020;5:406-11. [PMID: 32445369 DOI: 10.1093/jalm/jfz027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
9 |
Bayart JL, Favresse J, Stoefs A, Closset M, Roy T, Fillée C, Rodriguez-Villalobos H, Kabamba-Mukadi B, Gruson D. Biotin interferences: Have we neglected the impact on serological markers? Clin Chim Acta 2020;503:107-12. [PMID: 31978405 DOI: 10.1016/j.cca.2020.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
10 |
Robier C, Kolbus N, Demel U. Anti-streptavidin antibodies as a cause of false-positive results of streptavidin-based autoantibody assays. Clinical Chemistry and Laboratory Medicine (CCLM) 2019;58:e5-e7. [DOI: 10.1515/cclm-2019-0500] [Reference Citation Analysis]
|
11 |
Verougstraete N, Berth M, Vaneechoutte M, Delanghe J, Callewaert N. Interference of anti-streptavidin antibodies in immunoassays: a very rare phenomenon or a more common finding? Clinical Chemistry and Laboratory Medicine (CCLM) 2020;58:1673-80. [DOI: 10.1515/cclm-2019-1064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
12 |
Favresse J, Gruson D, Gheldof D. Comment on "High doses of biotin can interfere with immunoassays that use biotin-strept(avidin) technologies: Implications for individuals with biotin-responsive inherited metabolic disorders". Mol Genet Metab Rep 2019;21:100506. [PMID: 31467852 DOI: 10.1016/j.ymgmr.2019.100506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|